Evaluation of the Duration of Action and Comparative Effectiveness of Lisdexamfetamine Dimesylate and Behavioral Treatment in Youth With ADHD in a Quasi-Naturalistic Setting

J Atten Disord. 2015 Jul;19(7):578-90. doi: 10.1177/1087054712452915. Epub 2012 Aug 28.

Abstract

Objective: This study compared the relative effects of three treatment conditions: long-acting stimulant medication (MED), behavior modification, and medication/behavioral treatments combined (COM) in children with ADHD.

Method: A total of 25 children, aged 6 to 12 years, received the three treatment conditions during a 7-week Summer Treatment Program in an alternating treatments design. Counselors completed behavioral ratings from 0.5 to 12.5 hr post dose, and parents completed nighttime ratings.

Results: Ratings for SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham) and for following instructions indicated COM and MED improved symptoms over BEH treatment beginning 3 hr post dose (p = .008), with ratings maintained 12.5 hr post dose (p = .001 and .006). Results for frustration tolerance indicated significant improvement in all three conditions until 9 hr post dose.

Conclusion: MED and COM separated from BEH at 3 hr post dose, and sustained benefit was observed across the day for two of three measures. BEH appears to have an additive effect, extending the duration of frustration tolerance.

Keywords: ADHD; extended-release stimulant medication; multimodal treatment; psychosocial treatment.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Apathy
  • Attention Deficit Disorder with Hyperactivity / drug therapy
  • Behavior Therapy / methods*
  • Central Nervous System Stimulants / therapeutic use*
  • Child
  • Female
  • Frustration
  • Humans
  • Lisdexamfetamine Dimesylate / therapeutic use*
  • Male
  • Methylphenidate / therapeutic use
  • Parents
  • Prodrugs / therapeutic use
  • Treatment Outcome

Substances

  • Central Nervous System Stimulants
  • Prodrugs
  • Methylphenidate
  • Lisdexamfetamine Dimesylate